Theravance Biopharma, Inc. (TBPH)
After hours:
| Previous close | 9.14 |
| Open | 9.13 |
| Bid | 9.11 x 100 |
| Ask | 9.14 x 200 |
| Day's range | 9.06 - 9.27 |
| 52-week range | 8.21 - 11.98 |
| Volume | |
| Avg. volume | 369,988 |
| Market cap | 442.867M |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.00 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.40 |
ZacksStrength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
PR NewswireTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
Theravance Biopharma, Inc. (the "Company") (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM ET, featuring Horacio Kaufmann, MD, FAAN (Felicia B. Axelrod Professor of Neurology and Professor of Medicine at New York University Grossman School of Medicine) and Italo Biaggioni, MD (Professor of Medicine and Pharmacology Director, Vanderbilt Autonomic Dysfunction Center), who will discuss the unmet need and current treatment landscape
ZacksNektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
